Published in J Antimicrob Chemother on March 05, 2016
Orlistat in the treatment of obesity. Expert Opin Pharmacother (2000) 1.21
Modeling the relationship between drug lipophilicity and potential for an interaction with orlistat. J Clin Pharmacol (2011) 1.06
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther (2016) 0.81
Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages? PLoS One (2015) 0.81
Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. J Antimicrob Chemother (2017) 0.77
Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. J Antimicrob Chemother (2015) 0.75
Effect of hepatitis B and C clearance on atazanavir exposure. Eur J Clin Pharmacol (2015) 0.75
Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation. Hum Psychopharmacol (2016) 0.75
Renal function in HIV/HBV coinfected and HBV monoinfected patients on a long-term treatment with tenofovir in real life setting. Clin Exp Pharmacol Physiol (2016) 0.75
Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy. J Clin Virol (2015) 0.75
Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy? J Antimicrob Chemother (2016) 0.75
Is it time to revise linezolid dose in elderly patients? Eur J Clin Pharmacol (2017) 0.75
Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient. Eur J Clin Pharmacol (2015) 0.75
The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir. Eur J Clin Pharmacol (2017) 0.75
Effect of cobicistat on tenofovir disoproxil fumarate (TDF): what is true for TAF may also be true for TDF. J Acquir Immune Defic Syndr (2017) 0.75